| P2093 | author name string | Lane R Bushman | |
| | Eric G Meissner | |
| | John G McHutchison | |
| | Shyamasundaran Kottilil | |
| | Pamela Wolfe | |
| | Jennifer J Kiser | |
| | Joseph E Rower | |
| | Anu Osinusi | |
| | Zayani Sims | |
| | Leah C Jimmerson | |
| | Tess Petersen | |
| P2860 | cites work | A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Modification of Diet in Renal Disease Study Group | Q29614889 |
| | Mechanism of action of interferon and ribavirin in treatment of hepatitis C | Q29619805 |
| | Sofosbuvir for previously untreated chronic hepatitis C infection | Q29620137 |
| | Ledipasvir and sofosbuvir for previously treated HCV genotype 1 infection | Q29620620 |
| | IFNL4-ΔG genotype is associated with slower viral clearance in hepatitis C, genotype-1 patients treated with sofosbuvir and ribavirin | Q33596086 |
| | Hepatitis C guidance: AASLD-IDSA recommendations for testing, managing, and treating adults infected with hepatitis C virus | Q34044333 |
| | Mechanism of action of ribavirin in the combination treatment of chronic HCV infection | Q34618481 |
| | Sofosbuvir and ribavirin for hepatitis C genotype 1 in patients with unfavorable treatment characteristics: a randomized clinical trial | Q34624732 |
| | Variants in the ITPA gene protect against ribavirin-induced hemolytic anemia and decrease the need for ribavirin dose reduction | Q34913385 |
| | Measurement of intracellular ribavirin mono-, di- and triphosphate using solid phase extraction and LC-MS/MS quantification | Q34979638 |
| | Population pharmacokinetic modeling of plasma and intracellular ribavirin concentrations in patients with chronic hepatitis C virus infection | Q35169059 |
| | Pharmacokinetics of ribavirin in patients with hepatitis C virus | Q35648745 |
| | Population pharmacokinetics and pharmacodynamics of ribavirin in patients with chronic hepatitis C genotype 1 infection | Q36065593 |
| | Optimum ribavirin exposure overcomes racial disparity in efficacy of peginterferon and ribavirin treatment for hepatitis C genotype 1. | Q37032096 |
| | Ribavirin for chronic hepatitis C: and the mystery goes on. | Q37811184 |
| | Development and validation of a dried blood spot assay for the quantification of ribavirin using liquid chromatography coupled to mass spectrometry | Q38256679 |
| | Pharmacokinetics and absolute bioavailability of ribavirin in healthy volunteers as determined by stable-isotope methodology. | Q39471947 |
| | ITPA gene variants protect against anaemia in patients treated for chronic hepatitis C. | Q39920642 |
| | Inosine triphosphate protects against ribavirin-induced adenosine triphosphate loss by adenylosuccinate synthase function | Q39965118 |
| | Sofosbuvir and ribavirin prevent recurrence of HCV infection after liver transplantation: an open-label study | Q41724402 |
| | Simeprevir plus sofosbuvir, with or without ribavirin, to treat chronic infection with hepatitis C virus genotype 1 in non-responders to pegylated interferon and ribavirin and treatment-naive patients: the COSMOS randomised study | Q42202756 |
| | ABT-450/r-ombitasvir and dasabuvir with ribavirin for hepatitis C with cirrhosis | Q42225140 |
| | Retreatment of HCV with ABT-450/r-ombitasvir and dasabuvir with ribavirin | Q42225545 |
| | Efficacy of an interferon- and ribavirin-free regimen of daclatasvir, asunaprevir, and BMS-791325 in treatment-naive patients with HCV genotype 1 infection | Q42258200 |
| | Ribavirin pharmacokinetics in renal and liver transplant patients: evidence that it depends on renal function | Q42982324 |
| | Dosage of ribavirin in patients with hepatitis C should be based on renal function: a population pharmacokinetic analysis. | Q44228676 |
| | Marked elevation of erythrocyte ribavirin levels in interferon and ribavirin-induced anemia | Q44832671 |
| | The metabolism of ribavirin in erythrocytes and nucleated cells | Q46071227 |
| | Development and validation of a useful HPLC-UV method for quantification of total and phosphorylated-ribavirin in blood and erythrocytes of HCV+ patients. | Q50552379 |
| | Inosine triphosphatase polymorphisms and ribavirin pharmacokinetics as determinants of ribavirin-associate anemia in patients receiving standard anti-HCV treatment. | Q50553037 |
| | Pharmacokinetics, safety, and tolerability of ribavirin in hemodialysis-dependent patients. | Q50554702 |
| | Blood ribavirin concentration in high-dose ribavirin for adenovirus-induced haemorrhagic cystitis - a case report. | Q50569359 |
| P433 | issue | 8 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | pharmacokinetics | Q323936 |
| | ribavirin | Q421862 |
| | sofosbuvir | Q2502747 |
| P1104 | number of pages | 8 | |
| P304 | page(s) | 2322-2329 | |
| P577 | publication date | 2015-05-13 | |
| P1433 | published in | Journal of Antimicrobial Chemotherapy | Q6294770 |
| P1476 | title | Serum and cellular ribavirin pharmacokinetic and concentration-effect analysis in HCV patients receiving sofosbuvir plus ribavirin | |
| P478 | volume | 70 | |